Silver Book Fact

Raloxifene, a selective estrogen receptor modulator (SERM) has been shown to increase vertebral bone mineral density (BMD) by 2% to 3% after 3 years.

Ettinger B, Black D, Mitlak B, et al. Reduction of Vertebral Fracture Risk in Postmenopausal Women with Osteoporosis Treated with Raloxifene: Results from a 3-year randomized clinical trial. JAMA. 1999; 282(7): 637-45. http://jama.ama-assn.org/cgi/content/abstract/282/7/637?maxtoshow=&HITS=10&hits=10&RESULTFORMAT=&fulltext=Reduction+of+Vertebral+Fracture+Risk+in+Postmenopausal+Women+with+Osteoporosis+Treated+with+Raloxifene&searchid=1&FIRSTINDEX=0&resourcetype=HWCIT

Reference

Title
Reduction of Vertebral Fracture Risk in Postmenopausal Women with Osteoporosis Treated with Raloxifene: Results from a 3-year randomized clinical trial
Publication
JAMA
Publication Date
1999
Authors
Ettinger B, Black D, Mitlak B, et al
Volume & Issue
Volume 282, Issue 7
Pages
637-45
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • Raloxifene, a selective estrogen receptor modulator (SERM) has been shown to increase vertebral bone mineral density (BMD) by 2% to 3% after 3 years.  
  • A meta-analysis of clinical trials found that Vitamin D supplements reduced the risk of vertebral fractures by around 37%.  
  • Genetics can account for up to 75% of bone mineral density (BMD). Researchers have identified a gene that strongly influences peak bone mass in mice. The gene was not previously…  
  • Treatment with zoledronic acid over a 3-year period reduced risk of vertebral fracture by around 70% and risk of hip fracture by 41%, and increased bone mineral density (BMD) by…  
  • An increase in bone mineral density (BMD) testing and osteoporosis treatment was associated with a decrease in hip fracture incidence.